The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Mike Sathekge - One of the best experts on this subject based on the ideXlab platform.
-
Non-oncological applications of RGD-based single-Photon Emission Tomography and positron Emission Tomography agents.
European journal of nuclear medicine and molecular imaging, 2020Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike SathekgeAbstract:Non-invasive imaging techniques (especially single-Photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-Photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.
-
Non-oncological applications of RGD-based single-Photon Emission Tomography and positron Emission Tomography agents
European Journal of Nuclear Medicine and Molecular Imaging, 2020Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike SathekgeAbstract:Introduction Non-invasive imaging techniques (especially single-Photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-Photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract
Hank F. Kung - One of the best experts on this subject based on the ideXlab platform.
-
Small animal imaging with high resolution single Photon Emission Tomography.
Nuclear medicine and biology, 2003Co-Authors: Paul D. Acton, Hank F. KungAbstract:Molecular imaging of small animals in vivo is vital in the study of mouse and rat models of human diseases, and will provide important clues to the pathogenesis, progression and treatment of many disorders. Functional imaging of small animals using ultra-high resolution single Photon Emission Tomography (SPECT) should be a valuable tool in the molecular imaging armamentarium. SPECT has been used to study cerebral binding sites, to image the expression of reporter genes, and in applications in cardiology and oncology. In this review, we summarize the most recent developments in SPECT imaging of small animals, with particular reference to the types of systems available, their application, and some of the potential limitations.
-
Ultra-high resolution single Photon Emission Tomography imaging of the mouse striatum
European journal of nuclear medicine and molecular imaging, 2002Co-Authors: Paul D. Acton, Mei-ping Kung, Catherine Hou, Karl Plössl, Cindy L. Keeney, Hank F. KungAbstract:1. Acton PD, Choi SR, Plossl K, Kung HF. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single Photon Emission Tomography. Eur J Nucl Med 2002; DOI 10.1007/s00259-002-0776-7 2. Rosen GD, Williams AG, Capra JA, Connolly MT, Cruz B, Lu L, Airey DC, Kulkarni K, Williams RW. The Mouse Brain Library @ www.mbl.org. Int Mouse Genome Conference 2000; 14: 166 Paul D. Acton (✉) Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA e-mail: pacton@sunmac.spect.upenn.edu Tel.: +1-215-349-8374, Fax: +1-215-349-5035 Image of the month
Thomas Ebenhan - One of the best experts on this subject based on the ideXlab platform.
-
Non-oncological applications of RGD-based single-Photon Emission Tomography and positron Emission Tomography agents.
European journal of nuclear medicine and molecular imaging, 2020Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike SathekgeAbstract:Non-invasive imaging techniques (especially single-Photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-Photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.
-
Non-oncological applications of RGD-based single-Photon Emission Tomography and positron Emission Tomography agents
European Journal of Nuclear Medicine and Molecular Imaging, 2020Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike SathekgeAbstract:Introduction Non-invasive imaging techniques (especially single-Photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-Photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract
Paul D. Acton - One of the best experts on this subject based on the ideXlab platform.
-
Small animal imaging with high resolution single Photon Emission Tomography.
Nuclear medicine and biology, 2003Co-Authors: Paul D. Acton, Hank F. KungAbstract:Molecular imaging of small animals in vivo is vital in the study of mouse and rat models of human diseases, and will provide important clues to the pathogenesis, progression and treatment of many disorders. Functional imaging of small animals using ultra-high resolution single Photon Emission Tomography (SPECT) should be a valuable tool in the molecular imaging armamentarium. SPECT has been used to study cerebral binding sites, to image the expression of reporter genes, and in applications in cardiology and oncology. In this review, we summarize the most recent developments in SPECT imaging of small animals, with particular reference to the types of systems available, their application, and some of the potential limitations.
-
Ultra-high resolution single Photon Emission Tomography imaging of the mouse striatum
European journal of nuclear medicine and molecular imaging, 2002Co-Authors: Paul D. Acton, Mei-ping Kung, Catherine Hou, Karl Plössl, Cindy L. Keeney, Hank F. KungAbstract:1. Acton PD, Choi SR, Plossl K, Kung HF. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single Photon Emission Tomography. Eur J Nucl Med 2002; DOI 10.1007/s00259-002-0776-7 2. Rosen GD, Williams AG, Capra JA, Connolly MT, Cruz B, Lu L, Airey DC, Kulkarni K, Williams RW. The Mouse Brain Library @ www.mbl.org. Int Mouse Genome Conference 2000; 14: 166 Paul D. Acton (✉) Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA e-mail: pacton@sunmac.spect.upenn.edu Tel.: +1-215-349-8374, Fax: +1-215-349-5035 Image of the month
-
Single Photon Emission Tomography Imaging in Parkinsonian Disorders: A Review
Behavioural neurology, 2000Co-Authors: Paul D. Acton, P. David MozleyAbstract:Parkinsonian symptoms are associated with a number of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Pathological evidence has shown clearly that these disorders are associated with a loss of neurons, particularly in the nigrostriatal dopaminergic pathway. Positron Emission Tomography (PET) and single Photon Emission Tomography (SPECT) now are able to visualise and quantify changes in cerebral blood flow, glucose metabolism, and dopaminergic function produced by parkinsonian disorders. Both PET and SPECT have become important tools in the differential diagnosis of these diseases, and may have sufficient sensitivity to detect neuronal changes before the onset of clinical symptoms. Imaging is now being utilised to elucidate the genetic contribution to Parkinson’s disease, and in longitudinal studies to assess the efficacy and mode of action of neuroprotective drug and surgical treatments. This review summarises recent applications of SPECT imaging in the study of parkinsonian disorders, with particular reference to the increasing role it is playing in the understanding, diagnosis and management of these diseases.
-
Positron Emission Tomography and Single-Photon Emission Tomography in the Diagnosis of Parkinson’s Disease
Contemporary Neuroscience, 1Co-Authors: Paul D. ActonAbstract:Parkinsonian symptoms are associated with a number of neurodegenerative disorders, such as Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Positron Emission Tomography (PET) and single-Photon Emission Tomography (SPECT) now are able to visualize and quantify changes in cerebral blood flow, glucose metabolism, and neurotransmitter function produced by parkinsonian disorders. Both PET and SPECT have become important tools in the differential diagnosis of these diseases and may have sufficient sensitivity to detect neuronal changes before the onset of clinical symptoms. Imaging is now being used to elucidate the genetic contribution to Parkinson’s disease and in longitudinal studies to assess the efficacy and mode of action of neuroprotective drug and surgical treatments.
Marilyn Pérez - One of the best experts on this subject based on the ideXlab platform.
-
Brain single-Photon Emission Tomography with technetium-99m hexamethylpropylene amine oxime in adolescents with initial-stage schizophrenia
European journal of nuclear medicine, 1995Co-Authors: Juan F Batista, María C. Galiano, Leonel A. Torres, María C. Hernández, Felix Sosa, Alejandro Perera, Marilyn PérezAbstract:The objective of this study was to search for regional cerebral blood flow (rCBF) abnormalities in adolescents with initial-stage schizophrenia by means of brain single-Photon Emission Tomography (SPET) using technetium-99m hexamethylpropylene amine oxime (HMPAO). SPET studies were performed on a homogeneous sample of 15 carefully selected adolescents with a recent diagnosis of schizophrenia, and without previous electroconvulsive or antipsychotic drug treatment. Computed Tomography (CT) and electro-encephalographic (EEG) studies were performed in all patients. Qualitative and semiquantitative analysis of99mTc-HMPAO SPET studies showed an impaired rCBF in 12 patients (80%). The most common pattern was a decreased uptake of99mTc-HMPAO in the frontal lobes, usually in the left hemisphere. Conventional and quantitative EEG was positive in 12 (80%) and 15 (100%) patients, respectively. CT findings were positive in two patients (13%). There was a high level of concordance between SPET and EEG results and between SPET and clinical features (P>0.05). This study suggests that previously untreated patients in the first stages of schizophrenia present functional abnormalities that are revealed by brain SPET.